Using cell free DNA (cfDNA) and RNA (cfRNA) in the diagnosis and monitoring of primary and metastatic CNS tumors.

Authors

Maher Albitar, Ahmad Charifa, Sally Agersborg, Omar Butt, Adam Albitar, Na Tosha N Gatson, Andre Goy, Santosh Kesari

Published in

The journal of liquid biopsy. Volume 14. Pages 100500. Epub Sep 12, 2026.

Abstract

Cerebrospinal fluid (CSF) is a relatively accessible biospecimen, and liquid biopsy (LBx) testing using next-generation sequencing (NGS) provides actionable information on genomic abnormalities that can guide clinical decisions and therapeutic selection. To evaluate the potential clinical utility of CSF LBx, we analyzed real-world LB testing data from 1391 CSF samples.
CSF samples were submitted for clinical testing with various referring diagnoses, including primary brain tumors and metastatic tumors. NGS testing of cell-free DNA and RNA (cfDNA and cfRNA) as well as cellular RNA was performed using a targeted 302-gene DNA panel and a targeted RNA panel encompassing more than 1600 genes.
Of all samples, 231 (16.6%) were completely negative for any abnormality, 69 (5.0%) showed findings consistent with clonal hematopoiesis of indeterminate potential (CHIP), 2 (0.1%) demonstrated B-cell clonality alone, and 14 (1.0%) showed chromosomal abnormalities without identified mutations. The remaining 1075 cases (78.4%) were positive for mutations with or without additional abnormalities, consistent with primary or metastatic malignancy. cfRNA levels were extremely low in the majority of cases, with expression levels near zero across a significant number of genes. Nevertheless, cellular and cfRNA were adequate for the detection of fusion genes in 68 cases (4.9%) and CAR-T constructs in 5 cases (0.4%) of lymphoid neoplasms previously treated with CAR-T therapy, including cases in which CAR-T cells were undetectable in peripheral blood.
These findings suggest that LBx using combined DNA and RNA NGS testing of CSF is a reliable approach that yields potentially practice-changing clinical information.

PMID:
42779982
Bibliographic data and abstract were imported from PubMed on 24 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.